Literature DB >> 26780337

Radiographic patterns and survival of patients with early and late brain metastases in EGFR wild type and mutant non small cell lung cancer.

Ren Yuan1, Andrew Yamada2, Britta Weber3, Cheryl Ho4.   

Abstract

Brain metastasis (BM) in NSCLC is a negative prognostic indicator. In the era of EGFR mutations we evaluated the difference between early (≤6 months from diagnosis) versus late BM (>6 months), in EGFR wild type (WT) and mutant (MT) NSCLC patients with respect to radiographic patterns and overall survival (OS). A retrospective study was conducted of referred patients with non-squamous NSCLC with known EGFR mutation status treated for BM from Mar 2010-Dec 2012. Radiographic patterns, treatment and survival were collected. 430 patients were identified: 327 WT (207 early vs. 120 late) and 103 MT (65 early vs. 38 late). Early and late BM radiographic patterns were similar in EGFR WT patients. In EGFR MT there was a trend towards multiple lesions in the late compared to early BM group. OS from initial diagnosis early BM: WT 7.1 months versus MT 19.9 months (p < 0.001). OS from initial diagnosis late BM: WT 24.9 months versus MT 25.6 months (p = 0.51). In multivariate analysis chemotherapy, single lesion and late BM were associated with better survival in WT patients whereas age, and systemic treatment but not BM timing or single lesion were predictive of better outcomes in MT patients. In early BM, EGFR MT have an OS comparable to late BM. In contrast, early BM EGFR WT have a significantly reduced survival compared to late BM. The positive outcome in EGFR MT may be secondary to systemic control and EGFR TKI penetrance across the blood brain barrier.

Entities:  

Keywords:  Brain metastasis; EGFR mutation; Prognosis; Timing; Wild type

Mesh:

Substances:

Year:  2016        PMID: 26780337     DOI: 10.1007/s11060-016-2057-5

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  25 in total

1.  Patterns and predictors of first-line chemotherapy use among adults with advanced non-small cell lung cancer in the cancer research network.

Authors:  Debra P Ritzwoller; Nikki M Carroll; Thomas Delate; Mark C Hornbrook; Lawrence Kushi; Erin J Aiello Bowles; Jared M Freml; Karl Huang; Elizabeth T Loggers
Journal:  Lung Cancer       Date:  2012-09-27       Impact factor: 5.705

2.  Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor.

Authors:  Britta Weber; Michael Winterdahl; Ashfaque Memon; Boe S Sorensen; Susanne Keiding; Leif Sorensen; Ebba Nexo; Peter Meldgaard
Journal:  J Thorac Oncol       Date:  2011-07       Impact factor: 15.609

3.  A nomogram for individualized estimation of survival among patients with brain metastasis.

Authors:  Jill S Barnholtz-Sloan; Changhong Yu; Andrew E Sloan; Jaime Vengoechea; Meihua Wang; James J Dignam; Michael A Vogelbaum; Paul W Sperduto; Minesh P Mehta; Mitchell Machtay; Michael W Kattan
Journal:  Neuro Oncol       Date:  2012-04-27       Impact factor: 12.300

4.  Predictors for patterns of brain relapse and overall survival in patients with non-small cell lung cancer.

Authors:  Simon Guo-Jeng Tang; Chen-Kan Tseng; Pei-Kwei Tsay; Chih-Hung Chen; John Wen-Cheng Chang; Ping-Chin Pai; Ji-Hong Hong
Journal:  J Neurooncol       Date:  2005-06       Impact factor: 4.130

5.  Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System.

Authors:  Jill S Barnholtz-Sloan; Andrew E Sloan; Faith G Davis; Fawn D Vigneau; Ping Lai; Raymond E Sawaya
Journal:  J Clin Oncol       Date:  2004-07-15       Impact factor: 44.544

6.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Authors:  Lecia V Sequist; James Chih-Hsin Yang; Nobuyuki Yamamoto; Kenneth O'Byrne; Vera Hirsh; Tony Mok; Sarayut Lucien Geater; Sergey Orlov; Chun-Ming Tsai; Michael Boyer; Wu-Chou Su; Jaafar Bennouna; Terufumi Kato; Vera Gorbunova; Ki Hyeong Lee; Riyaz Shah; Dan Massey; Victoria Zazulina; Mehdi Shahidi; Martin Schuler
Journal:  J Clin Oncol       Date:  2013-07-01       Impact factor: 44.544

7.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

Authors:  Giorgio Vittorio Scagliotti; Purvish Parikh; Joachim von Pawel; Bonne Biesma; Johan Vansteenkiste; Christian Manegold; Piotr Serwatowski; Ulrich Gatzemeier; Raghunadharao Digumarti; Mauro Zukin; Jin S Lee; Anders Mellemgaard; Keunchil Park; Shehkar Patil; Janusz Rolski; Tuncay Goksel; Filippo de Marinis; Lorinda Simms; Katherine P Sugarman; David Gandara
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

8.  Metastatic brain tumors from non-small cell lung cancer with EGFR mutations: distinguishing influence of exon 19 deletion on radiographic features.

Authors:  Akimasa Sekine; Terufumi Kato; Eri Hagiwara; Takeshi Shinohara; Takanobu Komagata; Tae Iwasawa; Hiroaki Satoh; Katsumi Tamura; Tomotaka Kasamatsu; Kenji Hayashihara; Takefumi Saito; Hiroshi Takahashi; Takashi Ogura
Journal:  Lung Cancer       Date:  2012-02-13       Impact factor: 5.705

9.  Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial.

Authors:  David W Andrews; Charles B Scott; Paul W Sperduto; Adam E Flanders; Laurie E Gaspar; Michael C Schell; Maria Werner-Wasik; William Demas; Janice Ryu; Jean-Paul Bahary; Luis Souhami; Marvin Rotman; Minesh P Mehta; Walter J Curran
Journal:  Lancet       Date:  2004-05-22       Impact factor: 79.321

10.  Referral and treatment patterns among patients with stages III and IV non-small-cell lung cancer.

Authors:  Bernardo H L Goulart; Carolina M Reyes; Catherine R Fedorenko; David G Mummy; Sacha Satram-Hoang; Lisel M Koepl; David K Blough; Scott D Ramsey
Journal:  J Oncol Pract       Date:  2013-01       Impact factor: 3.840

View more
  5 in total

1.  Impact of EGFR mutation and ALK rearrangement on the outcomes of non-small cell lung cancer patients with brain metastasis.

Authors:  Suresh K Balasubramanian; Mayur Sharma; Vyshak A Venur; Philipp Schmitt; Rupesh Kotecha; Samuel T Chao; John H Suh; Lilyana Angelov; Alireza M Mohammadi; Michael A Vogelbaum; Gene H Barnett; Xuefei Jia; Nathan A Pennell; Manmeet S Ahluwalia
Journal:  Neuro Oncol       Date:  2020-02-20       Impact factor: 12.300

2.  Imaging Pattern of Diffuse Intrapulmonary Metastases in Lung Cancer Was Associated with Poor Prognosis to Epidermal Growth Factor Receptor Inhibitors.

Authors:  Yang Fu; Yuan Tang; Yue Zheng; Yue-Yun Chen; Ye Hong; Pei-Pei Wang; Qing Li; Ting Liu; Zhen-Yu Ding
Journal:  Cancer Manag Res       Date:  2020-11-17       Impact factor: 3.989

3.  Individualized Nomogram for Predicting Survival in Patients with Brain Metastases After Stereotactic Radiosurgery Utilizing Driver Gene Mutations and Volumetric Surrogates.

Authors:  Cheng Zhou; Changguo Shan; Mingyao Lai; Zhaoming Zhou; Junjie Zhen; Guanhua Deng; Hainan Li; Juan Li; Chen Ren; Jian Wang; Ming Lu; Liang Zhang; Taihua Wu; Dan Zhu; Feng-Ming Spring Kong; Longhua Chen; Linbo Cai; Lei Wen
Journal:  Front Oncol       Date:  2021-05-13       Impact factor: 6.244

4.  The impact of EGFR mutation status and single brain metastasis on the survival of non-small-cell lung cancer patients with brain metastases.

Authors:  Yuya Fujita; Manabu Kinoshita; Tomohiko Ozaki; Koji Takano; Kei Kunimasa; Madoka Kimura; Takako Inoue; Motohiro Tamiya; Kazumi Nishino; Toru Kumagai; Haruhiko Kishima; Fumio Imamura
Journal:  Neurooncol Adv       Date:  2020-05-28

5.  MicroRNA-330-3p promotes brain metastasis and epithelial-mesenchymal transition via GRIA3 in non-small cell lung cancer.

Authors:  Chunhua Wei; Ruiguang Zhang; Qian Cai; Xican Gao; Fan Tong; Jihua Dong; Yu Hu; Gang Wu; Xiaorong Dong
Journal:  Aging (Albany NY)       Date:  2019-09-08       Impact factor: 5.682

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.